In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection ...
In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site ...
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
Decentralized trial models have demonstrated real gains in enrollment performance and patient access, but operational switching costs, fragmented technology stacks, and unresolved gaps in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results